A Multicenter, Randomized, Double-Blind and Parallel-Comparison Clinical Study for the Treatment of Chronic Urticaria and for Effects on QTc Interval with Ebastine

QI Jun,YU Rui-yao,LI Heng-Jin,FAN Jian-feng,ZHANG Jian-zhong,CAI Lin,LI Wen-hai,ZHAO Jun-yin,WANG Zeng-fang,ZHAO Hui
DOI: https://doi.org/10.3321/j.issn:1003-3734.2005.05.030
2005-01-01
Abstract:Objective: To evaluate the efficacy and safety of ebastine for patients with chronic urticaria and the effects of ebastine on the QTc interval. Methods: Among 196 patients with chronic urticaria enrolled in a multicentral, randomized, double-blind, double-analog, parallel comparison clinical trial, 188 were randomized to orally receive either ebastine (n=90, 10mg) or loratadine (n=98, 10mg) once daily for 14 days. Results: No statistical difference in the overall efficacy rate of ebastine and loratadine was found [70.10% vs. 60.61% (P0.05)]. The incidence of adverse events of ebastine and loratadine were 9.28% vs. 6.06%.The QTc was not shown significant changes between two groups. Conclusion: Ebastine was an alternative to loratadine in the treatment of chronic urticaria.
What problem does this paper attempt to address?